



BSI Standards Publication

Guidance on aspects of a risk-based approach to assuring sterility of terminally sterilized, single-use health care products that is unable to withstand processing to achieve maximally a sterility assurance level of 10^{-6}

National foreword

This Published Document is the UK implementation of ISO/TS 19930:2017.

The UK participation in its preparation was entrusted to Technical Committee CH/198, Sterilization and Associated Equipment and Processes.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2017
Published by BSI Standards Limited 2017

ISBN 978 0 580 95161 9

ICS 11.080.01

Compliance with a British Standard cannot confer immunity from legal obligations.

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 30 November 2017.

Amendments/corrigenda issued since publication

Date	Text affected
------	---------------

Guidance on aspects of a risk-based approach to assuring sterility of terminally sterilized, single-use health care product that is unable to withstand processing to achieve maximally a sterility assurance level of 10⁻⁶

Document d'orientation sur les aspects d'une approche, fondée sur l'appréciation du risque, permettant d'assurer la stérilité des produits de santé à usage unique, soumis à une stérilisation terminale y compris ceux ne pouvant pas supporter un traitement atteignant un niveau d'assurance de la stérilité maximal de 10⁻⁶



COPYRIGHT PROTECTED DOCUMENT

© ISO 2017. Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword.....	iv
Introduction.....	v
1 Scope.....	1
2 Normative references.....	2
3 Terms and definitions.....	7
4 Assurance of sterility and sterility assurance level (SAL).....	6
5 Management responsibility.....	9
6 Compatibility of product with a sterilization process.....	10
6.1 Requirements in sterilization standards.....	10
6.2 Selecting and assessing materials and product.....	10
7 Strategies to achieve a maximal SAL of 10⁻⁶.....	11
8 Considerations if a maximal SAL of 10⁻⁶ cannot be achieved.....	14
8.1 General.....	14
8.2 Risk management considerations.....	15
8.3 Risk management output.....	16
9 Label claims.....	17
10 Establishing the sterilization process.....	18
11 Specific considerations for validation, routine monitoring and control, and product release from sterilization.....	18
12 Assessment of change.....	19
Annex A (informative) Illustration of the sequence of activities in selecting and justifying an alternative SAL.....	21
Bibliography.....	22

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 193, *Sterilization of health care products*.

Introduction

A sterile health care product is one that is free of viable microorganisms. International Standards that specify requirements for validation and routine control of sterilization processes require, when it is necessary to supply a sterile health care product, that adventitious microbiological contamination of that health care product prior to sterilization be minimized. Even so, health care product produced under standard manufacturing conditions in accordance with the requirements for quality management systems (see, for example, ISO 13485) could, prior to sterilization, have microorganisms on them, albeit in low numbers. Such health care product is non-sterile. The purpose of sterilization is to inactivate or remove the microbiological contaminants and thereby transform the non-sterile health care product into sterile ones.

Compliance with the requirements of International Standards for development, validation and routine control of sterilization processes ensures that the sterilization process is both reliable and reproducible so that predictions can be made, with reasonable confidence, that there is a low probability of there being a viable microorganism present on a health care product after sterilization.

Specification of this probability is a matter for regulatory authorities and can vary from country to country.

For example, the European Standards Organization has published EN 556-1. EN 556-1 has been harmonized in the European Union and also been adopted in a number of countries outside Europe, for example Australia and China. EN 556-1 specifies that a sterility assurance level (SAL) of 10^{-6} or less (e.g. 10^{-7}) has to be achieved in order to designate a terminally sterilized medical device as sterile. EN 556-1 includes an explanatory note that specifies that permission for acceptance of a sterility assurance level of greater than 10^{-6} (e.g. 10^{-5}) may be sought through appropriate regulatory bodies and such permission requires consideration of the individual situation, including consideration of the risk assessment undertaken by the manufacturer of the medical device.

In the USA, the American National Standard ANSI/AAMI ST67 specifies that a maximal sterility assurance level of 10^{-6} is required for the majority of terminally sterilized health care product. ST67 also indicates that

- a) there are circumstances for which a greater maximal sterility assurance level of 10^{-3} can be acceptable for certain product, e.g. product that does not contact breached skin or compromised tissue, and
- b) when product cannot withstand a terminal sterilization process that achieves maximally a SAL of 10^{-6} , a greater sterility assurance level (e.g. 10^{-5}) might be acceptable for that product.

There is health care product that is unable to withstand a terminal sterilization process achieving maximally a SAL of 10^{-6} . This might be because some or all of the materials that constitute the product are sensitive to one or more traditional sterilization processes, for example cellular or biologically-based components.

The purpose of this document is to provide general guidance on the considerations to be taken into account in selecting a SAL for health care product that is unable to withstand terminal sterilization to meet the general requirement to achieve maximally a SAL of 10^{-6} . Particularly, the document gives advice in relation to fulfilling the EN 556-1:2001, Note to 4.1 and AAMI ST67:2011, 4.2.4.

It is recognized that this topic is contentious for some regulatory agencies, conformity assessment bodies, manufacturers, contract sterilizers and national standards bodies. Some see development of this document as a potential move to relax the current regulatory quality requirements to supply product as sterile. This is not the intention. This document states clearly that a decision to approve a SAL other than 10^{-6} for a specific product resides solely with the relevant regulatory agency. A cautious approach has been taken during development of this document and ongoing diligence is maintained to ensure that the spirit in which this document is intended is not misconstrued. The purpose of this document is to promote discussion between interested parties and to bridge a gap in existing standards and regulations. This document provides much-needed guidance on technical aspects when considering an

alternative SAL to 10^{-6} for identified high clinical need, terminally sterilized product that is unable to withstand the processing conditions necessary to achieve maximally a SAL of 10^{-6} .

This document is intended to be applied by process developers, manufacturers of health care product to be sterilized and organizations responsible for the sterilization of health care product.

Currently in preview, click buy full version

Guidance on aspects of a risk-based approach to assuring sterility of terminally sterilized, single-use health care product that is unable to withstand processing to achieve maximally a sterility assurance level of 10^{-6}

1 Scope

This document provides guidance on identifying the aspects to be considered as part of a risk-based approach to selecting a sterility assurance level (SAL) for terminally sterilized, single-use health care product that is unable to withstand processing to achieve maximally a SAL of 10^{-6} .

In addition, this document provides

- a) background information on the assurance of sterility and sterility assurance level, and
- b) guidance on strategies that can allow the achievement of a maximal SAL of 10^{-6} .

This document describes the elements of a quality management system which are applied to enable the appropriate selection of a SAL for terminally sterilized, single-use health care product that is unable to withstand processing to achieve maximally a SAL of 10^{-6} .

NOTE It is not a requirement of the International Standard for development, validation and routine control of a sterilization process to have a full quality management system. Attention is drawn to the standard for quality management systems (see ISO 13485) that controls all stages of the lifecycle of health care product.

This document is applicable to sterilization processes in which microorganisms are inactivated by physical and/or chemical means.

This document does not apply

- to selecting a maximal SAL greater than 10^{-6} for health care product that is able to withstand processing to achieve maximally a SAL of 10^{-6} ;
- in cases where a maximal SAL of 10^{-6} is required and an alternative SAL is not allowed;
- in cases where a maximal SAL of greater than 10^{-6} (e.g. 10^{-3}) has been accepted by regulatory authorities within their jurisdiction for health care product for defined use;
- to the sterilization of used or reprocessed health care product;
- to sterilization of health care product by filtration.

This document does not describe detailed procedures for assessing microbial inactivation.

This document does not specify requirements for the development, validation and routine control of a process for inactivating the causative agents of spongiform encephalopathies such as scrapie, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. Specific recommendations have been produced in particular countries for the processing of materials potentially contaminated with these agents.

NOTE See also ISO 22442-1, ISO 22442-2 and ISO 22442-3.

This document does not supersede or modify published International Standards for particular sterilization processes.